PTJ
EWTX icon

Paul Tudor Jones’s Edgewise Therapeutics EWTX Stock Holding History

Paul Tudor Jones’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,100
Closed -$871K – 3813
2025
Q4 		$871K Sell
35,100
-3,600
-9% -$72.3K ﹤0.01% 2364
2025
Q3 		$628K Buy
+38,700
New +$549K ﹤0.01% 2566

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Paul Tudor Jones's EWTX Position: Q2 2026 in Review

Paul Tudor Jones increased its Edgewise Therapeutics (EWTX) stake by 90% in Q2 2026, buying an estimated $932K and bringing the position to 56,934 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

Paul Tudor Jones first reported a position in EWTX in Q2 2024 and has held it in 7 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Paul Tudor Jones held 56,934 shares of Edgewise Therapeutics worth $2.31M as of Q2 2026.
  • Paul Tudor Jones bought 27,045 Edgewise Therapeutics shares in Q2 2026, an estimated $932K.
  • Edgewise Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1848 holding.
  • Paul Tudor Jones first reported a position in Edgewise Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.